Pharmaron Chooses Reaxys® To Enhance Productivity and Competitiveness
Reaxys is an online workflow solution used by research chemists to fuel their drug discovery processes.
Frankfurt, Germany, August 29, 2011 – Elsevier, a world-leading provider of scientific, technical and medical information products and services, announced today that Pharmaron, a premier drug R&D service provider for the pharmaceutical and biotech industry, has signed a multi-year contract with Elsevier, which will provide unlimited Reaxys access to all Pharmaron researchers. Reaxys will enable Pharmaron to continue to consolidate its scientific excellence and to stay competitive in drug R&D, and also ensure that Pharmaron has the best possible resources available to provide high-quality research and solutions to their customers.
“Our partners depend on the high-quality drug R&D services that we provide. The information our scientists have access to is a critical componentof our drug R&D services,” said Dr. Tongqian Chen, Senior Vice President of Chemistry at Pharmaron. “Reaxys’ proven track record in providing an unparalleled quality of information will allow our scientists in the labs to plan and execute in a more productive manner. We are delighted to have Elsevier as our scientific information providing partner and look forward to the productive collaboration.”
Pharmaron is a key player in the Chinese CRO industry, a preferred drug R&D service provider to global pharmaceutical and chemical companies. The increased emphasis on partnership and productivity has made validated information access indispensible. Consequently access to Reaxys’ chemical information will be a significant aspect in helping Pharmaron continue to be a highly competitive and dynamic player in the industry.
“Reaxys provides the relevant information that enables researchers to work effectively; we are committed to ensuring that researchers can immediately take their findings from Reaxys and apply them effectively in the lab,” said Mark van Mierle, Managing Director, Pharma and Biotech Group, Elsevier. “We look forward to continuing to support Pharmaron’s ongoing R&D work.”
Reaxys® is a registered trademark ownedandprotected by Elsevier Properties SA and used under license.
# # #
Pharmaron is a premier R&D service provider for the pharmaceutical and biotech industries. Founded in 2003, Pharmaron invests in its people and facilities enabling the company to provide high quality R&D service across a number of disciplines, including chemistry, biology, DMPK, pharmacology and chemical development. Pharmaron is steadily growing to meet the needs of its customers. With more than 1,200 employees and operations in China and the U.S., Pharmaron delivers superior scientific services while maintaining close communication with customers. The company’s current clients include small and large pharmaceutical companies in North America, Europe and Japan. Pharmaron's mission is to provide the highest quality R&D services while helping customers advance their projects in a timely and cost effective manner.
Elsevier is a world-leading provider of information solutions that enhance the performance of science, health, and technology professionals, empowering them to make better decisions, deliver better care, and sometimes make groundbreaking discoveries that advance the boundaries of knowledge and human progress. Elsevier provides web-based, digital solutions — among them ScienceDirect, Scopus, Elsevier Research Intelligence, and ClinicalKey — and publishes nearly 2,200 journals, including The Lancet and Cell, and over 25,000 book titles, including a number of iconic reference works.
The company is part of Reed Elsevier Group PLC, a world leading provider of professional information solutions in the Science, Medical, Legal and Risk and Business sectors, which is jointly owned by Reed Elsevier PLC and Reed Elsevier NV. The ticker symbols are REN (Euronext Amsterdam), REL (London Stock Exchange), RUK and ENL (New York Stock Exchange).Media contact
Vice President, Global Corporate Relations Elsevier
+1 215 239 3508